Grifols
GRFS · NASDAQ
Bulios Fair Price
$9.91
35.6% upside
Current Price
$7.31
According to Bulios Fair Price, GRFS is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Grifols, S.A. is a global Spanish pharmaceutical and biotechnology company specializing in the production of plasma-derived medicines and healthcare products. The company focuses on producing immunoglobulins, albumin, and other plasma-based products that are essential for the treatment of various diseases, including immunological and neurological disorders. Grifols also develops diagnostic tools and systems for hospitals and clinics. The company has a broad global presence and operates in over 30 countries worldwide.
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Jose Ignacio Abia Buenache
Employees
25,258
Headquarters
Barcelona
Upcoming events
Earnings
Upcoming earnings report